Core Insights - The establishment of the Heptagon Pharmaceuticals-AstraZeneca Innovation Laboratory in Beijing marks a significant milestone in the collaboration between the two companies, enhancing their strategic partnership in drug development [1][2] - Heptagon Pharmaceuticals has formed partnerships with multiple multinational pharmaceutical companies, accumulating over $10 billion in total collaboration agreements [1] - The collaboration aims to develop next-generation multi-specific antibody therapies targeting immune diseases, tumors, and other conditions, with a focus on integrating AI in drug design and clinical development [2] Company Developments - Heptagon Pharmaceuticals has expanded its self-developed pipeline from 5 products to over 20, covering various therapeutic areas including oncology, inflammation, immune diseases, metabolic diseases, and central nervous system disorders [2] - The newly unveiled innovation laboratory is equipped with a comprehensive antibody drug innovation development platform and an AI wet-dry laboratory platform, which are set to accelerate the research and development process [1] Strategic Collaborations - The partnership includes a diversified collaboration model comprising research cooperation, equity investment, and the establishment of the Beijing Innovation Center, which injects new momentum into innovative drug development [1] - The collaboration with AstraZeneca is seen as a breakthrough in traditional Sino-foreign pharmaceutical partnerships, potentially leading to more innovative outcomes [2]

消息面上，据和铂医药官微消息，10月25日，和铂医药-阿斯利康创新实验室在北京正式揭牌，标志着 双方合作进一步深化，新一代抗体药物从发现到优化的全流程研发进入"加速通道"。至此，双方已形 成"研发合作+股权投资+建立北京创新中心"的多元化合作模式，为创新药物研发注入全新动能。 据介绍，今年3月，和铂医药与阿斯利康达成全球战略合作，共同研发针对免疫性疾病、肿瘤及其他多 种疾病的新一代多特异性抗体疗法，并在北京建设创新实验室，推动前沿科研落地。经过数月筹备，该 创新实验室全面就绪，和铂医药抗体药物创新开发平台与AI干湿实验室平台已完成搭建，即将正式投 入使用，助力多领域新一代治疗性抗体研发。 和铂医药-B(02142)涨超6%，截至发稿，涨6.35%，报13.23港元，成交额993.94万港元。 ...

据介绍，今年3月，和铂医药与阿斯利康达成全球战略合作，共同研发针对免疫性疾病、肿瘤及其他多 种疾病的新一代多特异性抗体疗法，并在北京建设创新实验室，推动前沿科研落地。经过数月筹备，该 创新实验室全面就绪，和铂医药抗体药物创新开发平台与AI干湿实验室平台已完成搭建，即将正式投 入使用，助力多领域新一代治疗性抗体研发。 智通财经APP获悉，和铂医药-B(02142)涨超6%，截至发稿，涨6.35%，报13.23港元，成交额993.94万港 元。 消息面上，据和铂医药官微消息，10月25日，和铂医药-阿斯利康创新实验室在北京正式揭牌，标志着 双方合作进一步深化，新一代抗体药物从发现到优化的全流程研发进入"加速通道"。至此，双方已形 成"研发合作+股权投资+建立北京创新中心"的多元化合作模式，为创新药物研发注入全新动能。 ...

Core Insights - The establishment of the Harbour Mice-AstraZeneca Innovation Laboratory in Beijing marks a significant milestone in the collaboration between Harbour Mice and AstraZeneca, creating a diversified cooperation model that includes R&D collaboration, equity investment, and the establishment of an innovation center [1][3][5] Group 1: Collaboration and Innovation - The partnership aims to develop next-generation multi-specific antibody therapies targeting immune diseases, tumors, and other conditions, leveraging advanced technologies and resources [3][5] - The newly unveiled innovation laboratory integrates Harbour Mice's fully human antibody technology with AstraZeneca's expertise in disease biology, clinical development, and AI drug design, serving as a strategic hub for innovation [5][6] - The collaboration has evolved from a single licensing agreement to a comprehensive ecosystem-building approach, enhancing trust and cooperation between the two companies [7] Group 2: Technological Advancements - Harbour Mice's antibody technology platform, including the Harbour Mice and HCAb PLUS™ systems, addresses traditional challenges in antibody development, enabling the creation of fully human antibodies and expanding applications to bispecific antibodies, ADCs, CAR-T, RNA therapies, and AI [6][7] - The integration of AI and big data into the antibody development process is expected to significantly accelerate the research and development of new therapeutic antibodies [7][8] Group 3: Future Outlook - Harbour Mice plans to expand its pipeline from 5 to over 20 products, covering various therapeutic areas such as oncology, inflammation, metabolic diseases, and central nervous system disorders [8] - The company aims to strengthen its innovation capabilities and deepen platform empowerment, positioning itself as a key player in the global pharmaceutical innovation chain [8]